Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) in the first-line (1L)

被引：0
|
作者：
Paluri, Ravi Kumar
Silver, Michelle
Cockrum, Paul
Dennen, Syvart
机构：
[1] Wake Forest Univ, Winston Salem, NC USA
[2] Genesis Res Grp, Hoboken, NJ USA
[3] Ipsen Biopharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16322
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-line chemotherapies with FOLFIRINOX or gemcitabine plus nab-paclitaxel for unresectable pancreatic ductal adenocarcinoma in Japanese daily clinical practice
    Yano, M.
    Terashima, T.
    Yamashita, T.
    Miyazawa, M.
    Mizuno, H.
    Nomura, Y.
    Omura, H.
    Takata, Y.
    Ooishi, N.
    Shugo, H.
    Yamada, K.
    Takabatake, H.
    Takatori, H.
    Hodo, Y.
    Nishino, R.
    Hayashi, T.
    Mizukoshi, E.
    Kaneko, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Fukahori, Masaru
    Okabe, Yoshinobu
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Makiyama, Akitaka
    Taguchi, Hiroki
    Honda, Takuya
    Ushijima, Tomoyuki
    Miwa, Keisuke
    Shibuki, Taro
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [23] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Masaru Fukahori
    Yoshinobu Okabe
    Mototsugu Shimokawa
    Taiga Otsuka
    Futa Koga
    Yujiro Ueda
    Junichi Nakazawa
    Azusa Komori
    Satoshi Otsu
    Shiho Arima
    Akitaka Makiyama
    Hiroki Taguchi
    Takuya Honda
    Tomoyuki Ushijima
    Keisuke Miwa
    Taro Shibuki
    Kenta Nio
    Yasushi Ide
    Norio Ureshino
    Toshihiko Mizuta
    Kenji Mitsugi
    Tsuyoshi Shirakawa
    Scientific Reports, 13
  • [24] The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
    Prejac, Juraj
    Hamzic, Dora Tomek
    Librenjak, Niksa
    Gorsic, Irma
    Kekez, Domina
    Plestina, Stjepko
    MEDICINE, 2022, 101 (39) : E30566
  • [25] Baseline characteristics and second-line treatment for metastatic pancreatic adenocarcinoma (mPAC) patients receiving first-line FOLFIRINOX, gemcitabine plus nab-paclitaxel or gemcitabine-monotherapy in routine clinical practice across Europe
    Prager, G.
    Macarulla Mercade, T.
    Mellbring, A.
    Taieb, J.
    Carrato, A.
    Melisi, D.
    Westphalen, B.
    D'Esquermes, N.
    Ferreras, A.
    de Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29 : 93 - 93
  • [26] First-line (1L) full dose (f) and modified (m) FOLFIRINOX and gemcitabine plus nab-paclitaxel (GN) treatment (tx) for metastatic pancreatic adenocarcinoma (mPAC) patients (pts) in routine clinical practice across Europe
    Taieb, J.
    Carrato, A.
    Westphalen, B.
    Melisi, D.
    Prager, G.
    Macarulla Mercade, T.
    Mellbring, A. B. C.
    d'Esquermes, N.
    Ferreras, A.
    de Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Real-world analysis of treatment patterns examining nab-Paclitaxel plus Gemcitabine (nab-P plus G) versus FOLFIRINOX (FFX) in first-line (10 treatment (tx) of metastatic pancreatic adenocarcinoma (MPAC) in a US community oncology setting
    Braiteh, Fadi S.
    Patel, Manish
    Parisi, Monika
    Ni, Quanhong
    Park, Si Yeon
    Faria, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Dosing patterns and treatment patterns in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line
    MacEwan, Joanna P.
    Silver, Michelle
    Cockrum, Paul
    Sanders, Chad
    Kim, George P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX
    Kim, George P.
    Parisi, Monika F.
    Patel, Manish B.
    Pelletier, Corey L.
    Belk, Kathy W.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (05) : 559 - 565
  • [30] Modified FOLFIRINOX as second-line therapy in 140 patients with pancreatic adenocarcinoma patients who have failed first-line treatment using gemcitabine and nab-paclitaxel
    Farrell, D.
    Fitzgerald, S.
    Daly, A.
    Knox, B.
    Divilly, J.
    Robinson, M.
    Gallagher, L.
    Burke, P.
    Dean, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S148 - S148
12345